Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Phase I, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors

NCT05639153 is registered in ClinicalTrials.gov with Zhejiang Doer Biologics Co., Ltd. as lead sponsor.

NCT NCT05639153
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05639153 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Phase I, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors
Lead sponsor
Zhejiang Doer Biologics Co., Ltd.
Phase
Phase 1
Overall status
Terminated
Start date
May 13, 2022
Completion date
March 18, 2026
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant neoplasm of digestive system